Refractory Edema

691 views 24 slides Apr 17, 2020
Slide 1
Slide 1 of 24
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24

About This Presentation

Refreactory Edema = Edema that is refractory to typically effective doses of loop diuretics. 


Slide Content

Causes and Treatment of Refractory Edema

Generalized edema can occur in a variety of disorders, including heart failure , cirrhosis (where ascites is usually most prominent), and the nephrotic syndrome Significant edema is not always present in CKD, but CKD can produce resistance to diuretic treatment. Edematous patients generally respond to the combination of dietary Na restriction , treatment of the underlying disease process , and diuretic therapy , usually with a loop diuretic. However, some patients are resistant to typical doses of diuretics.

Refractory Edema is defined as Edema that is refractory to typically effective doses of loop diuretics. 

CAUSES OF REFRACTORY EDEMA Inadequate diuretic dose or frequency Decreased oral diuretic absorption Decreased loop diuretic tubular secretion Enhanced tubular sodium reabsorption High salt intake Drugs that interfere with diuretic action MANAGEMENT OF REFRACTORY EDEMA Pretreatment evaluation Stepwise approach to refractory edema Intensification of oral loop diuretic therapy Combination oral diuretic therapy Intravenous loop diuretic bolus therapy Continuous infusion option in patients who respond to bolus therapy Patients unresponsive to intravenous diuretics Benefit from a supine posture Outline

CAUSES OF REFRACTORY EDEMA Inadequate diuretic dose or frequency Decreased intestinal absorption of oral diuretics Decreased diuretic secretion into tubular fluid Increased sodium reabsorption at sites in the nephron other than those inhibited by the diuretic Excess sodium intake Concomitant administration of other classes of drugs that interfere with diuretic action

1.Inadequate diuretic dose or frequency Diuretics do not produce natriuresis until a threshold rate of drug excretion is attained . If, for example, a patient does not respond to 40 mg of  Furosemide , the dose may not have exceeded this threshold. Thus, the single dose should be increased to 60 or 80 mg , rather than giving the 40 mg dose twice a day . Once a single effective dose has been determined, it is most commonly administered multiple times per day at a frequency that is individualized to the diuretic needs of the patient and the pharmacokinetic profile of the agent chosen.

Relation between the rate of furosemide excretion and the increase in sodium excretion in normals (solid line) and patients with HF (dashed line). A diuresis is not seen until a threshold rate of furosemide excretion is reached. Patients with HF show relative resistance at a given rate of diuretic excretion due to increased sodium reabsorption in other nephron segments.

2.Decreased oral diuretic absorption In patients with heart failure, decreased intestinal perfusion, reduced intestinal motility, and perhaps also mucosal edema can reduce the rate of diuretic absorption, and therefore reduce the rate of diuretic delivery into the tubular lumen by as much as 50 to 70 %. This reduced delivery of diuretic into the renal tubule may keep it below the threshold . Thus, patients with acute decompensated heart failure typically require initial intravenous (IV) therapy.

3.Decreased loop diuretic tubular secretion Loop diuretics must enter the tubular fluid in order to exert their diuretic effect . Loop diuretics are highly (≥95 %) protein bound. As a result, they primarily enter the tubular lumen by secretion by the proximal tubule, not by glomerular filtration. Patients who do not respond to usual doses of loop diuretic therapy may be resistant because of decreased diuretic secretion into the tubular lumen. This may result from decreased renal perfusion in patients with heart failure (due to the reduced cardiac output ), cirrhosis (due to renal vasoconstriction ), and renal impairment (due to competitive inhibition of tubular diuretic secretion by high concentrations of organic anions that accumulate when the GFR is reduced).

4.Enhanced tubular sodium reabsorption   Some patients have partial or relatively complete resistance to a loop diuretic despite adequate secretion of the diuretic into the tubular fluid ( ie , despite having the same rate of urinary diuretic excretion as normal controls) . This problem is often due to increased tubular sodium reabsorption by nephron segments other than the loop of Henle . The decreased response to the action of a diuretic that results from increased sodium reabsorption in other nephron segments has been called the diuretic braking phenomenon

5.High salt intake Maintenance of a high Na intake can prevent net sodium loss and a reduction in extracellular fluid volume, even if there is an appropriate natriuretic response to diuretics.

6. Drugs that interfere with diuretic action   NSAIDs , which reduce the synthesis of vasodilator and natriuretic prostaglandins and impair diuretic responsiveness Thiazolidinediones , such as  Rosiglitazone , increase renal salt retention as a result of upregulation of the ENaC in the collecting ducts and also increase proximal tubule sodium reabsorption 

MANAGEMENT OF REFRACTORY EDEMA Pretreatment evaluation Stepwise approach to refractory edema Intensification of oral loop diuretic therapy Combination oral diuretic therapy Intravenous loop diuretic bolus therapy Continuous infusion option in patients who respond to bolus therapy Patients unresponsive to intravenous diuretics Benefit from a supine posture

Pretreatment Evaluation Exclude excessive sodium intake – It is important to evaluate the patient's dietary sodium intake and attempt to reduce it, if excessive. To estimate sodium intake, a 24-hour urine should be collected. Confirm that the patient requires a reduction in extracellular fluid volume – While the mere presence of residual edema or pulmonary congestion (crackles or breathlessness) is suggestive, the decision to further reduce the extracellular fluid volume requires careful clinical judgement.  Before intensifying diuretic therapy, the following steps should be taken:

Stepwise approach to refractory edema 1- Intensification of oral loop diuretic therapy   Starting dose (oral or intravenous) Maximum effective dose (higher individual doses or more frequent dosing intervals are unlikely to produce substantial additional diuresis) Maximal recommended daily dose (greater daily total doses are associated with a risk for toxicity) Furosemide Furosemide Furosemide Heart failure 20 mg once or twice daily 80 mg 3 times daily 600 mg Cirrhotic ascites 40 mg once or twice daily 40 mg 3 times daily 160 mg Nephrotic syndrome 40 mg once or twice daily 120 mg 3 times daily 600 mg Chronic kidney disease ‡ 200 mg 3 times daily 600 mg Acute kidney injury 80 mg once or twice daily 500 mg once 600 mg ‡ Initial diuretic doses for patients with CKD depend on its stage .

Oral Furosemide Therapy   Starting dose (oral or intravenous) Maximum effective dose (higher individual doses or more frequent dosing intervals are unlikely to produce substantial additional diuresis) Maximal recommended daily dose (greater daily total doses are associated with a risk for toxicity) Heart failure 20 mg once or twice daily 80 mg 3 times daily 600 mg Cirrhotic ascites 40 mg once or twice daily 40 mg 3 times daily 160 mg Nephrotic syndrome 40 mg once or twice daily 120 mg 3 times daily 600 mg Chronic kidney disease ‡ 200 mg 3 times daily 600 mg Acute kidney injury 80 mg once or twice daily 500 mg once 600 mg ‡ Initial diuretic doses for patients with CKD depend on its stage .

Stepwise approach to refractory edema 2. Combination oral diuretic therapy When an adequate response to loop diuretics is not obtained, concurrent administration of a thiazide-like ( Metolazone ) or thiazide-type ( Hydrochlorothiazide ) diuretic to block distal sodium chloride reabsorption should be employed: Without hypokalemia    Metolazone  ( 5 to 10 mg once daily initially, increased to a maximum dose of 20 mg once daily) , although  Hydrochlorothiazide  ( 25 to 50 mg twice daily initially, increased to a maximum dose of 200 mg per day) is likely just as effective. With hypokalemia    P otassium-sparing diuretic first ( eg ,  Amiloride   or, particularly in patients with heart failure, a mineralocorticoid receptor antagonist). 

Stepwise approach to refractory edema 3- Intravenous loop diuretic bolus therapy   The initial dose of IV loop diuretic should be ~ 2 or 2.5 times the patient's total maintenance daily oral dose If there is little or no response to the initial dose, the dose should be doubled at two-hour intervals , as needed, up to the maximum recommended doses rather than repeated at the same dose . Patients who do not have an adequate response to a maximal dose of one IV loop diuretic are unlikely to respond to another loop diuretic since their mechanisms of action are similar.

Stepwise approach to refractory edema 3- Intravenous loop diuretic bolus therapy   Loop diuretics should not be administered IV as a rapid "push ." Although there are no data related to the optimal time over which a single IV dose of a loop diuretic should be administered, the following approach seems reasonable; the doses are given for  Furosemide  : 20 to 40 mg over five minutes 60 to 120 mg over 20 minutes 160 to 200 mg over 40 to 50 minutes (4 mg/min) In patients who fail to respond to maximal IV bolus doses of a loop diuretic, a thiazide-like or thiazide-type diuretic can be coadministered .

3- Intravenous loop diuretic bolus therapy   a. Continuous infusion option in patients who respond to bolus therapy In patients with refractory edema who respond to an IV bolus of a loop diuretic but need ongoing diuresis   I nitiate a continuous loop diuretic infusion. Continuous diuretic therapy may be less ototoxic than bolus therapy and maintains a sustained effective rate of diuretic excretion. 

An IV loading dose of 40 to 80 mg of  F uros emide  is typically given over five minutes prior to initiating the continuous infusion. After the loading dose, the starting infusion rate with  Furosemide  varies with the level of kidney function: Acute Kidney Injury or CKD with eGFR less than 30 mL/min per 1.73 m 2 )   I nitial  Furosemide  infusion rate of 20 mg per hour . If the diuresis is not sustained, a second bolus is given followed by a higher infusion rate of 40 mg per hour. eGFR greater than or equal to 30 mL/min per 1.73 m 2   Initial  Furosemide  infusion rate of 5 mg per hour. If the diuresis is not sustained, a second bolus is given followed by a higher infusion rate of 10 mg per hour. This rate may then be increased further to the maximum recommended furosemide infusion rate of 40 mg per hour if response to lower doses is poor. Continuous Infusion Protocol

3- Intravenous loop diuretic bolus therapy   b. Patients unresponsive to intravenous diuretics   The excess fluid can be removed by ultrafiltration during renal replacement therapy.

Benefit from a Supine posture The supine position was associated with significantly higher mean creatinine clearance (100 versus 66 mL/min) and diuretic response The upright position was associated with significant increases in plasma norepinephrine, renin, and aldosterone.

Thank You
Tags